Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial

worldpharmanewsDecember 17, 2019

Tag: AstraZeneca , Daiichi Sankyo , trastuzumab deruxtecan , HER2-positive metastatic breast cancer

PharmaSources Customer Service